OncoMatch/Clinical Trials/NCT04536805
Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin
Is NCT04536805 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Metformin for prostate cancer.
Treatment: Metformin — This phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
WHO 0–1
Prior therapy
Must have received: external radiotherapy — prostate lodge
Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy
Must have received: hormone therapy
Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy
Must have received: radical prostatectomy
for prostatic adenocarcinoma previously treated by radical prostatectomy
Cannot have received: metformin
Treatment with metformin in the last 3 months prior to inclusion
Cannot have received: investigational drug
Treatment with any investigational drug or participation in a clinical trial within 30 days prior to inclusion
Lab requirements
Kidney function
Creatinine clearance >= 45 mL/min
Creatinine clearance < 45 mL/min [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify